Autoinjectors, Pen Injectors, And Prefilled Syringes: How Thermo Fisher Scientific Is Advancing Self-Administered Therapies

Patients in clinical trials shouldn't have to choose between accessing treatment and maintaining their quality of life. As self-administration becomes the standard across more therapy areas, your fill-finish strategy needs to keep pace, without introducing new risks or timeline delays into your program.

Selecting a development and manufacturing partner with the right device assembly capabilities early can mean the difference between smooth phase transitions and costly program disruptions. Thermo Fisher's scale- and platform-flexible capabilities span manual to fully automated fill-finish, covering autoinjectors, pen injectors, and prefilled syringes alongside traditional vial formats.

This means you can progress from Phase 1/2 vials into more complex primary packaging formats in Phase 2/3 and beyond with a single, integrated partner, reducing cross-functional handoffs and keeping your supply chain strategy coherent as your needs evolve. Right-sized equipment scaling helps you maximize operational efficiency at every stage, while end-to-end integration supports faster timelines from clinical development through commercial launch. The result is a more predictable path to getting your therapy to patients in the format that best supports their daily lives.

Watch now to see how Thermo Fisher's device assembly capabilities can support your biologic program from first-in-human studies through commercialization.